Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 120

1.

NS5A inhibitors in the treatment of hepatitis C.

Pawlotsky JM.

J Hepatol. 2013 Aug;59(2):375-82. doi: 10.1016/j.jhep.2013.03.030. Epub 2013 Apr 6. Review.

PMID:
23567084
[PubMed - indexed for MEDLINE]
Free Article
2.

Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir.

Karino Y, Toyota J, Ikeda K, Suzuki F, Chayama K, Kawakami Y, Ishikawa H, Watanabe H, Hernandez D, Yu F, McPhee F, Kumada H.

J Hepatol. 2013 Apr;58(4):646-54. doi: 10.1016/j.jhep.2012.11.012. Epub 2012 Nov 22.

PMID:
23178977
[PubMed - indexed for MEDLINE]
3.

Daclatasvir: potential role in hepatitis C.

Lee C.

Drug Des Devel Ther. 2013 Oct 16;7:1223-33. doi: 10.2147/DDDT.S40310. eCollection 2013. Review. Erratum in: Drug Des Devel Ther. 2014;8:325.

PMID:
24204123
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection.

Herbst DA, Reddy KR.

Expert Opin Investig Drugs. 2013 Oct;22(10):1337-46. doi: 10.1517/13543784.2013.826189. Epub 2013 Aug 9. Review.

PMID:
23931586
[PubMed - indexed for MEDLINE]
5.

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.

Chayama K, Takahashi S, Toyota J, Karino Y, Ikeda K, Ishikawa H, Watanabe H, McPhee F, Hughes E, Kumada H.

Hepatology. 2012 Mar;55(3):742-8. doi: 10.1002/hep.24724. Epub 2012 Jan 30.

PMID:
21987462
[PubMed - indexed for MEDLINE]
6.

Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?

Halfon P, Sarrazin C.

Liver Int. 2012 Feb;32 Suppl 1:79-87. doi: 10.1111/j.1478-3231.2011.02716.x. Review.

PMID:
22212577
[PubMed - indexed for MEDLINE]
7.

Hepatitis C virus resistance to protease inhibitors.

Halfon P, Locarnini S.

J Hepatol. 2011 Jul;55(1):192-206. doi: 10.1016/j.jhep.2011.01.011. Epub 2011 Feb 1. Review.

PMID:
21284949
[PubMed - indexed for MEDLINE]
Free Article
8.

Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein.

Belda O, Targett-Adams P.

Virus Res. 2012 Dec;170(1-2):1-14. doi: 10.1016/j.virusres.2012.09.007. Epub 2012 Sep 23. Review.

PMID:
23009750
[PubMed - indexed for MEDLINE]
9.

Characterization of Hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885.

Wong KA, Worth A, Martin R, Svarovskaia E, Brainard DM, Lawitz E, Miller MD, Mo H.

Antimicrob Agents Chemother. 2013 Dec;57(12):6333-40. doi: 10.1128/AAC.02193-12. Epub 2013 Jul 22.

PMID:
23877691
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Comprehensive analysis for viral elements and interleukin-28B polymorphisms in response to pegylated interferon plus ribavirin therapy in hepatitis C virus 1B infection.

Maekawa S, Sakamoto M, Miura M, Kadokura M, Sueki R, Komase K, Shindo H, Komatsu N, Shindo K, Kanayama A, Ohmori T, Amemiya F, Takano S, Yamaguchi T, Nakayama Y, Kitamura T, Inoue T, Okada S, Enomoto N.

Hepatology. 2012 Nov;56(5):1611-21. doi: 10.1002/hep.25826.

PMID:
22577043
[PubMed - indexed for MEDLINE]
11.

The hepatitis C virus NS5A protein and response to interferon alpha: mutational analyses in patients with chronic HCV genotype 3a infection from India.

Goyal A, Hofmann WP, Hermann E, Traver S, Hissar SS, Arora N, Blum HE, Zeuzem S, Sarrazin C, Sarin SK.

Med Microbiol Immunol. 2007 Mar;196(1):11-21. Epub 2006 Sep 6.

PMID:
16955308
[PubMed - indexed for MEDLINE]
12.

Mutations in non-structural 5A and rapid viral response to pegylated interferon-α-2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C.

Yano Y, Seo Y, Miki A, Saito M, Kato H, Hamano K, Oya M, Ouchi S, Fujisawa T, Yamada H, Yamashita Y, Tani S, Hirohata S, Yoon S, Kitajima N, Kitagaki K, Kawara A, Nakashima T, Yu H, Maeda T, Azuma T, El-Shamy A, Hotta H, Hayashi Y; Kobe Hepatitis Therapeutic Group.

Int J Mol Med. 2012 Nov;30(5):1048-52. doi: 10.3892/ijmm.2012.1093. Epub 2012 Aug 9.

PMID:
22899224
[PubMed - indexed for MEDLINE]
13.

Discovery of hepatitis C virus NS5A inhibitors as a new class of anti-HCV therapy.

Lee C.

Arch Pharm Res. 2011 Sep;34(9):1403-7. doi: 10.1007/s12272-011-0921-6. Review.

PMID:
21975800
[PubMed - indexed for MEDLINE]
14.

Analysis of sequences of hepatitis C virus NS5A genotype 1 in HIV-coinfected patients with a null response to nitazoxanide or peg-interferon plus ribavirin.

Sede M, Laufer N, Ojeda D, Gun A, Cahn P, Quarleri J.

Arch Virol. 2013 Sep;158(9):1907-15. doi: 10.1007/s00705-013-1687-6. Epub 2013 Apr 4.

PMID:
23553458
[PubMed - indexed for MEDLINE]
15.

A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C.

Lawitz EJ, Gruener D, Hill JM, Marbury T, Moorehead L, Mathias A, Cheng G, Link JO, Wong KA, Mo H, McHutchison JG, Brainard DM.

J Hepatol. 2012 Jul;57(1):24-31. doi: 10.1016/j.jhep.2011.12.029. Epub 2012 Feb 5.

PMID:
22314425
[PubMed - indexed for MEDLINE]
16.

Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor.

Plaza Z, Soriano V, Vispo E, del Mar Gonzalez M, Barreiro P, Seclén E, Poveda E.

Antivir Ther. 2012;17(5):921-6. doi: 10.3851/IMP2091. Epub 2012 Mar 21.

PMID:
22436385
[PubMed - indexed for MEDLINE]
17.

Antiviral strategies in hepatitis C virus infection.

Sarrazin C, Hézode C, Zeuzem S, Pawlotsky JM.

J Hepatol. 2012;56 Suppl 1:S88-100. doi: 10.1016/S0168-8278(12)60010-5. Review.

PMID:
22300469
[PubMed - indexed for MEDLINE]
18.

Sustained viral response in a hepatitis C virus-infected chimpanzee via a combination of direct-acting antiviral agents.

Olsen DB, Davies ME, Handt L, Koeplinger K, Zhang NR, Ludmerer SW, Graham D, Liverton N, MacCoss M, Hazuda D, Carroll SS.

Antimicrob Agents Chemother. 2011 Feb;55(2):937-9. doi: 10.1128/AAC.00990-10. Epub 2010 Nov 29.

PMID:
21115793
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life.

Guedj J, Dahari H, Rong L, Sansone ND, Nettles RE, Cotler SJ, Layden TJ, Uprichard SL, Perelson AS.

Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):3991-6. doi: 10.1073/pnas.1203110110. Epub 2013 Feb 19.

PMID:
23431163
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutations.

Pawlotsky JM, Germanidis G, Neumann AU, Pellerin M, Frainais PO, Dhumeaux D.

J Virol. 1998 Apr;72(4):2795-805.

PMID:
9525599
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk